This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Second View: Discussing Incyte Corp's Phase 3 results of LBA-1 Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma, as discussed at the ASH Annual Meeting.
Ticker(s): INCYWho's the expert?
Institution: Pinehurst Medical Clinic
- Hematology oncology physician at Pinehurst Medical Clinic serving patients at FirstHealth Outpatient Cancer Center located in Pinehurst North Carolina.
- Currently treats 30 patients with LR-MDS and also treats patients with Tazverik.
- Specializes in diagnosing and treating cancer and blood disorders: Anemia, Aplastic Anemia/Bone Marrow Failure, Bleeding Disorders, Bone Marrow/Stem Cell Transplantation, Leukemia, Low Platelet Counts, Low White Blood Cell Counts, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes.
Interview GoalThis conversation will focus on the current treatment landscape and potential use of LBA-1 Tafasitamab for follicular lymphoma.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
